Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-α and ribavirin: A prospective randomized controlled trial

Intervirology

Volumn 50, Issue 6, 2008, Pages 439-446

  Takaki, Shintaro ^a   Kawakami, Yoshiiku ^a   Imamura, Michio ^a   Aikata, Hiroshi ^a   Takahashi, Shoichi ^a   Ishihara, Hiroto ^b   Tsuji, Keiji ^c   Aimitsu, Shiomi ^d   Kawakami, Hiroiku ^e   Nakanishi, Toshio ^f   Kitamoto, Mikiya ^g   Moriya, Takashi ^g   Satoh, Kenichi ^g   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Chuden Hospital   (Japan)

^c HIROSHIMA CITY ASA HOSPITAL   (Japan)

^d ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^e Kawakami Clinic   (Japan)

^f Shobara Red Cross Hospital   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Anemia; Chronic hepatitis C; Combination therapy; Eicosapentaenoic acid; PEG interferon; Ribavirin

Indexed keywords

EPADEL S900; HEMOGLOBIN; ICOSAPENTAENOIC ACID; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANEMIA; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 39749134154     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000114718     Document Type: Article

References (38)